文献速递肺结节与肺癌

晚期非小细胞肺癌培美曲塞维持治疗期间肾功能损害的前瞻性队列研究

Renal impairment during pemetrexed maintenance in patients with advanced nonsmall cell lung cancer: a cohort study.
PubMed 文献 · Eur Respir J · 2018-10-25

该前瞻性多中心队列研究评估了晚期非小细胞肺癌患者培美曲塞维持治疗期间急性/慢性肾病的发生率、相关停药频率及危险因素。主要队列中30%的维持治疗患者发生急性肾病,其中62%进展为慢性肾病并停药;诱导期eGFR相对下降与维持期急性肾病风险独立相关。

要点

  • 培美曲塞维持治疗期间约30%患者发生急性肾病,部分进展为慢性肾病并停药。
  • 维持前eGFR较高及诱导期eGFR相对下降与维持期急性肾病风险相关。
  • 维持治疗期间需监测肾功能,肾功能损害可能影响后续抗肿瘤治疗。

核心结论

  • 培美曲塞维持治疗期间患者存在肾功能损害风险,可能危及后续抗肿瘤治疗。

研究设计与样本

  • 前瞻性多中心队列研究,纳入190例接受培美曲塞的IIIB/IV期非小细胞肺癌患者。
  • 主要队列149例开始诱导治疗,其中44例(30%)继续维持治疗;独立验证队列41例接受维持治疗。

主要发现

  • 主要队列维持治疗期间13例(30%)发生急性肾病,其中8例(62%)进展为慢性肾病并停药。
  • 独立队列维持治疗期间20例(49%)发生急性肾病,其中11例(55%)进展为慢性肾病,6例(30%)停药。
  • 维持前eGFR每增加5 mL·min-1 per 1.73 m2,急性肾病风险降低(OR 0.70,95% CI 0.54-0.90)。
  • 诱导前eGFR每增加5 mL·min-1 per 1.73 m2,急性肾病风险降低(OR 0.78,95% CI 0.62-0.98)。
  • 诱导期间eGFR相对下降每10%,急性肾病风险增加(OR 2.54,95% CI 1.36-4.74)。

临床怎么用

  • 培美曲塞维持治疗期间应定期监测肾功能,尤其关注诱导期eGFR下降的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Optimal survival benefit from different lines of anticancer treatment in advanced nonsmall cell lung cancer (NSCLC) requires conservation of renal function. We evaluated the development of renal impairment during pemetrexed maintenance.In a prospective multicentre cohort study, we evaluated the incidence of acute/chronic kidney disease (AKD/CKD), its related treatment discontinuation frequency and associated clinical variables with AKD in patients with stage IIIB/IV NSCLC treated with pemetrexed maintenance. We validated the findings in an independent cohort.190 patients received pemetrexed. In the primary cohort, 149 patients started induction, of whom 44 patients (30%) continued maintenance. In the independent cohort, 41 patients received maintenance. During maintenance 13 patients (30%) developed AKD, leading to CKD and treatment discontinuation in eight patients (62%) in the primary cohort. Higher estimated glomerular filtration rate (eGFR) (per unit 5 mL·min-1 per 1.73 m2) before maintenance and induction (OR 0.70, 95% CI 0.54-0.90 and OR 0.78, 95% CI 0.62-0.98, respectively) and relative decline (per 10%) in eGFR during induction (OR 2.54, 95% CI 1.36-4.74) were associated with AKD during maintenance. In the independent cohort, 20 patients (49%) developed AKD, leading to CKD in 11 patients (55%) and treatment discontinuation in six patients (30%).Patients are at risk for renal impairment during pemetrexed maintenance, which may jeopardise further lines of anticancer treatment.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Visser S, Huisbrink J, van 't Veer NE, et al. Renal impairment during pemetrexed maintenance in patients with advanced nonsmall cell lung cancer: a cohort study. Eur Respir J. 2018. PMID: 30139775. doi:10.1183/13993003.00884-2018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。